The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Live Herpes Zoster Vaccine Fails to Provide Long-Term Protection in RA Patients on Tofacitinib

Live Herpes Zoster Vaccine Fails to Provide Long-Term Protection in RA Patients on Tofacitinib

April 21, 2020 • By Lisa Rapaport

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters Health)—The live herpes zoster vaccine does not provide reliable long-term protection in rheumatoid arthritis (RA) patients taking tofacitinib, a recent study suggests.

You Might Also Like
  • The Effect of Tofacitinib on Live Vaccine Responses
  • Herpes Zoster & Tofacitinib
  • Tofacitinib After Live Shingles Vaccination Does Not Impair Immunogenicity

Current ACR guidelines conditionally recommend that patients with RA who are 50 years and older be vaccinated against herpes zoster prior to starting therapy with the Janus kinase (JAK) inhibitor tofacitinib or with biologic disease modifying antirheumatic drugs (bDMARDs). Herpes zoster incidence is approximately twofold higher with tofacitinib as it is with bDMARDs, the study team notes.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

For the current analysis, researchers looked at data on 100 RA patients who took tofacitinib after receiving the live herpes zoster vaccine, before the recombinant zoster vaccine became available in 2017. This included 46 people on an average dose of 5 mg and 54 people on an average dose of 10 mg two times per day.

Five patients developed herpes zoster, at 218, 280, 748,741, and 544 days post-vaccination, respectively. All cases were mild to moderate in severity and resolved with antiviral treatment.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Three of the five patients who developed herpes zoster during the study had undetectable varicella zoster virus (VZV) cell-mediated immunity after vaccination, both at baseline and at week 6.

The other two patients who developed herpes zoster responded adequately to vaccination by both IgG and ELISPOT measures, but had lower than average VZV IgG levels at baseline and Week 6, the study team writes in Annals of the Rheumatic Diseases.1

“The study suggests the live vaccine is likely less protective in rheumatology patients who subsequently start JAK inhibitors as compared to the general population,” says lead study author Kevin Winthrop, MD, MPD, of Oregon Health & Science University School of Medicine, Portland.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

“RA patients build less robust cell-mediated immunity after vaccination with this live vaccine as compared to the general population,” Dr. Winthrop says by email. “It is likely that less robust cellular immunity translates to less robust short-term and long-term protection.”

Although it’s possible that LZV booster vaccinations may improve vaccine efficacy, to date there is a lack of data on the use and timing of booster vaccinations, and no recommendations on the use of LZV booster vaccinations currently exist, the study team writes.

This highlights the importance of evaluating the newly approved subunit non-live vaccine (Shingrix) in patients with RA receiving tofacitinib, the authors write. The study was sponsored by Pfizer, maker of tofacitinib, and several authors on the study have received a variety of funding from Pfizer and several other drug companies.

Until Shingrix became FDA approved and commercially available, there was a great deal of reluctance to vaccinate immunocompromised patients against herpes zoster due to a theoretical concern that patients may develop the clinical disease of shingles from the live vaccine, says Eliza Chakravarty, MD, MS, an associate member in arthritis and clinical immunology at the Oklahoma Medical Research Foundation, Oklahoma City.

Most of the prior studies of the live herpes zoster vaccine in RA patients were small, and concentrated more on the risk of developing shingles after vaccination rather than actual short- or long-term protection from the vaccine, Dr. Chakravarty, who wasn’t involved in the current study, says by email.

Now, the concern from the new study is that the live vaccine doesn’t offer long-term protection against shingles, Dr. Chakravarty says.

“But, there is an available vaccine that has shown improved efficacy in healthy people,” Dr. Chakravarty adds. “We don’t know how strong or how long-lasting the efficacy of the new vaccine [Shingrix] is in people with RA, but there is no evidence now that we shouldn’t just be vaccinating with the new vaccine and not with Zostavax anymore.”


Reference

  1. Winthrop KL, Wouters A, Choy EH, et al. Long-term effectiveness of live herpes zoster vaccine in patients with rheumatoid arthritis subsequently treated with tofacitinib. Ann Rheum Dis. 2020 May;79(5):669–671. Epub 2020 Mar 11.

Pages: 1 2 | Multi-Page

Filed Under: Conditions, Rheumatoid Arthritis Tagged With: herpes zoster, Rheumatoid Arthritis (RA), shingles, Shingrix, Tofacitinib, vaccine

You Might Also Like:
  • The Effect of Tofacitinib on Live Vaccine Responses
  • Herpes Zoster & Tofacitinib
  • Tofacitinib After Live Shingles Vaccination Does Not Impair Immunogenicity
  • Herpes Zoster & the Risk of Stroke in Patients with Autoimmune Diseases

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)